Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing
- 16 April 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (17), 9477-9482
- https://doi.org/10.1073/pnas.1921335117
Abstract
Resolution of intestinal inflammation and wound repair are active processes that mediate epithelial healing at mucosal surfaces. Lipid molecules referred to as specialized proresolving mediators (SPMs) play an important role in the restorative response. Resolvin E1 (RvE1), a SPM derived from omega-3 fatty acids, has been reported to dampen intestinal inflammation by promoting anti-inflammatory responses including increased neutrophil spherocytosis and macrophage production of IL-10. Despite these observations, a role for RvE1 in regulating intestinal epithelial cell migration and proliferation during mucosal wound repair has not been explored. Using an endoscopic biopsy-based wound healing model, we report that RvE1 is locally produced in response to intestinal mucosal injury. Exposure of intestinal epithelial cells to RvE1 promoted wound repair by increasing cellular proliferation and migration through activation of signaling pathways including CREB, mTOR, and Src-FAK. Additionally, RvE1-triggered activation of the small GTPase Rac1 led to increased intracellular reactive oxygen species (ROS) production, cell-matrix adhesion, and cellular protrusions at the leading edge of migrating cells. Furthermore, in situ administration of RvE1-encapsulated synthetic targeted polymeric nanoparticles into intestinal wounds promoted mucosal repair. Together, these findings demonstrate that RvE1 functions as a prorepair lipid mediator by increasing intestinal epithelial cell migration and proliferation, and highlight potential therapeutic applications for this SPM to promote mucosal healing in the intestine.Keywords
Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK61739)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK72564)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK79392)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK059888)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK089763)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK055679)
- HHS | NIH | National Heart, Lung, and Blood Institute (R01-HL127236)
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (R01-EB024322)
- Crohn's and Colitis Foundation of America (544599)
This publication has 39 references indexed in Scilit:
- Resolvin E1 Promotes Bone Preservation Under Inflammatory ConditionsFrontiers in Immunology, 2018
- Protectin D1 n-3 DPA and resolvin D5 n-3 DPA are effectors of intestinal protectionProceedings of the National Academy of Sciences, 2017
- Resolvin E1 Reverses Experimental Periodontitis and DysbiosisThe Journal of Immunology, 2016
- Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and PathophysiologyJournal of Virology, 2016
- Is multiple sclerosis a proresolution deficiency disorder?Nutrition, 2012
- Accelerated Wound Healing by mTOR Activation in Genetically Defined Mouse ModelsPLOS ONE, 2010
- Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium–induced colitisInflammatory Bowel Diseases, 2010
- Resolvins E1 and D1 in Choroid-Retinal Endothelial Cells and Leukocytes: Biosynthesis and Mechanisms of Anti-inflammatory ActionsInvestigative Opthalmology & Visual Science, 2009
- Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cellsRegulatory Peptides, 2009
- Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and PathwaysAnnual Review of Immunology, 2007